Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from Summit Therapeutics outperformed
November 14, 2024